6 unknown. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Unknown 6 |
| Phase 2 | 3 | Unknown 3 |
Follow Amyloidosis: new trials by email Literature Review of Amyloidosis trials Research Report on Amyloidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FKC288 for Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis FKC288 - Light Chain Amyloidosis | Phase 1 | Unknown | Nanjing University School of Medicine | 12 | 2023-08-29 | 2023-11-15 |
| Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis AT-02, AT-02 (Placebo) - Amyloidosis; Systemic | Phase 1 | Unknown | Attralus, Inc. | 100 | 2022-09-01 | 2024-04-03 |
| APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma APG-2575+ Pd, APG-2575 + DRd - Multiple Myeloma, Amyloidosis | Phase 1 / Phase 2 | Unknown | Ascentage Pharma Group Inc. | 108 | 2021-12-23 | 2023-10-25 |
| Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis STI-6129 - Light Chain (AL) Amyloidosis | Phase 1 / Phase 2 | Unknown | Sorrento Therapeutics, Inc. | 60 | 2021-04-01 | 2023-01-17 |
| Antibiotics Against Amyloid Angiopathy Minocycline, Placebo - Cerebral Amyloid Angiopathy | Phase 1 / Phase 2 | Unknown | Leiden University Medical Center | 60 | 2020-12-02 | 2023-01-11 |
| Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer sargramostim, amifostine trihydrate, carboplatin - Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ | Phase 1 | Unknown | The Cleveland Clinic | 30 | 1997-11-01 | 2013-12-19 |
Immunoglobulin Light-chain Amyloidosis (3) · Multiple Myeloma (2) · Blast Crisis (1) · Burkitt Lymphoma (1) · Cerebral Amyloid Angiopathy (1) · Drug-Related Side Effects and Adverse Reactions (1) · Hodgkin Disease (1) · Immunoblastic Lymphadenopathy (1) · Leukemia (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Hairy Cell (1) · Leukemia, Large Granular Lymphocytic (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Accelerated Phase (1)
Metabolic Diseases (6) · Nutritional and Metabolic Diseases (6) · Proteostasis Deficiencies (6) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Paraproteinemias (4) · Cardiovascular Diseases (3) · Neoplasms, Plasma Cell (3) · Vascular Diseases (3) · Blood Protein Disorders (2) · Hematologic Diseases (2)
Amifostine (1) · Carboplatin (1) · Cyclophosphamide (1) · Dexamethasone (1) · GTP Cyclohydrolase (1) · Lisaftoclax (1) · Minocycline (1) · sargramostim (1)
Ascentage Pharma Group Inc. (1) · Attralus, Inc. (1) · Leiden University Medical Center (1) · Nanjing University School of Medicine (1) · Sorrento Therapeutics, Inc. (1) · The Cleveland Clinic (1)
United States (4) · Australia (1) · China (1) · Netherlands (1)
Anita D'Souza, MD (1) · George Thomas Budd, MD (1) · Jeffrey Zonder, MD (1) · Michael Rosenzweig, MD (1) · Vaishali Sanchorawala, MD (1) · Xianghua Huang, MD (1) · Yifan Zhai, MD, PhD (1)
2019 (1)